(Erstwhile UTI Pharma & Healthcare Fund) Table of Contents The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR
return of 14.9% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . NAV as on 28 Apr 25 ₹272.335 ↑ 3.89 (1.45 %) Net Assets (AUM) as on 31 Mar 2025 ₹1,042 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 1.04 Expense Ratio 2.38 % Sharpe Ratio 0.664 Information Ratio -0.23 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 28 Apr 25 Duration Returns 1 Month 1.5% 3 Month 4.7% 6 Month -2.7% 1 Year 21.3% 3 Year 20.3% 5 Year 22.1% 10 Year 15 Year Since launch 14.9% Historical Annual Returns
Year Returns 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% 2015 -9.7% Growth of 10k Over Years
Date Value 31 Mar 20 ₹10,000 31 Mar 21 ₹17,396 31 Mar 22 ₹19,596 31 Mar 23 ₹17,899 31 Mar 24 ₹27,884 31 Mar 25 ₹33,479 Asset Allocation
Asset Class Value Cash 0.79% Equity 99.21% Sector Allocation
Sector Value Health Care 98.03% Basic Materials 1.18% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 12% ₹121 Cr 700,000
↓ -25,000 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087Drug Manufacturers - Specialty & Generic 6% ₹61 Cr 420,000
↓ -44,949 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 4% ₹46 Cr 174,885
↓ -13,514 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 4% ₹45 Cr 396,000
↓ -36,608 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296Drug Manufacturers - Specialty & Generic 4% ₹42 Cr 275,250
↓ -34,061 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 4% ₹38 Cr 74,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 4% ₹37 Cr 56,271 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 532843Medical Care Facilities 3% ₹32 Cr 465,000
↓ -92,701 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 3% ₹32 Cr 56,000
↓ -5,480 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹31 Cr 63,840
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 2.92 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹272.335
↑ 3.89 -2.72 % 21.33 % 20.32 % 22.08 % UTI Healthcare Fund
Normal Dividend, Payout ₹210.477
↑ 3.01 -2.72 % 21.33 % 20.32 % 22.08 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹210.477
↑ 3.01 -2.72 % 21.33 % 20.32 % 22.08 % Data as on 28 Apr 25